AP NEWS

Global Monoclonal Antibodies Market Analysis & Outlook to 2022: Projected to Expand at a CAGR of Approx 15% with AbbVie, Amgen, Johnson & Johnson and Merck Leading - ResearchAndMarkets.com

January 3, 2019

DUBLIN--(BUSINESS WIRE)--Jan 3, 2019--The “Global Monoclonal Antibodies Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The monoclonal antibodies market will register a CAGR of about 15% by 2022.

Rise in the number of companies venturing into monoclonal antibodies space to drive market growth. To gain profits, the companies are investing huge amounts in the development of monoclonal antibodies. At present, companies are expanding their businesses to increase the development and sales of monoclonal antibodies.

Introduction of low cost biosimilar monoclonal antibodies

The introduction of biosimilars aimed at curbing the increasing year-over-year cost of healthcare and handling the economic pressure from the patient pool and governments to reduce healthcare expenses, could be instrumental in reducing the cost of medication and increasing patient access to treatment.

High cost of monoclonal antibodies

Monoclonal antibodies cost high, both at end-user stage as well as the development stage, primarily owing to the use of highly advanced and expensive facilities.

Key Players

AbbVie Amgen Johnson & Johnson Merck

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

Market definition Market sizing 2017 Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY APPLICATION

Segmentation by application Comparison by application Oncology - Market size and forecast 2017-2022 Immunology - Market size and forecast 2017-2022 Hematology - Market size and forecast 2017-2022 Others - Market size and forecast 2017-2022 Market opportunity by application

PART 09: MARKET SEGMENTATION BY ORIGIN OF MONOCLONAL ANTIBODIES

Segmentation by origin of monoclonal antibodies Murine antibodies Human antibodies Humanized antibodies Chimeric antibodies

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

Increasing cases of diseases like cancer and immunological disorders Rise in the number of companies venturing into the monoclonal antibodies space Growing pricing pressure in the monoclonal antibodies segment

PART 15: VENDOR LANDSCAPE

PART 16: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors AbbVie Amgen Johnson & Johnson Merck

For more information about this report visit https://www.researchandmarkets.com/research/pbhv4m/global_monoclonal?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190103005307/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Biopharmaceuticals

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/03/2019 06:15 AM/DISC: 01/03/2019 06:15 AM

http://www.businesswire.com/news/home/20190103005307/en

AP RADIO
Update hourly